OBJECTIVE: To trace the historical events leading to Richardson's clinical description of progressive supranuclear palsy (PSP) in the context of subsequent observations of its clinical heterogeneity and pathologic overlap with other tauopathies. BACKGROUND: Fifty years ago, Canadian neurologist J. Clifford Richardson identified patients in Toronto with a syndrome of supranuclear vertical gaze palsy, pseudobulbar palsy, axial rigidity-in-extension, and cognitive impairment. In his seminal description, Richardson predicted that further clinicopathologic observations would broaden the clinical syndrome and that this was unlikely to be a disorder restricted to the Toronto region. METHODS: The recollections of two of Richardson's contemporaries and archival material from his time were used as primary materials. Publications that follow the evolution of his observations were examined. RESULTS: Recent factor analysis of pathologically verified PSP cases has confirmed the accuracy and uniformity of the original classic clinical description of PSP and vindicated Richardson's prediction of clinical variants. Most notably, a presentation with Parkinson syndrome and absent gaze palsy has been identified, with less severe PSP-tau pathology. CONCLUSIONS: In recognition of his seminal observations, we propose that the classic clinical presentation of PSP-tau pathology be renamed Richardson's disease, and that the commonest clinical variant be termed PSP-parkinsonism.
OBJECTIVE: To trace the historical events leading to Richardson's clinical description of progressive supranuclear palsy (PSP) in the context of subsequent observations of its clinical heterogeneity and pathologic overlap with other tauopathies. BACKGROUND: Fifty years ago, Canadian neurologist J. Clifford Richardson identified patients in Toronto with a syndrome of supranuclear vertical gaze palsy, pseudobulbar palsy, axial rigidity-in-extension, and cognitive impairment. In his seminal description, Richardson predicted that further clinicopathologic observations would broaden the clinical syndrome and that this was unlikely to be a disorder restricted to the Toronto region. METHODS: The recollections of two of Richardson's contemporaries and archival material from his time were used as primary materials. Publications that follow the evolution of his observations were examined. RESULTS: Recent factor analysis of pathologically verified PSP cases has confirmed the accuracy and uniformity of the original classic clinical description of PSP and vindicated Richardson's prediction of clinical variants. Most notably, a presentation with Parkinson syndrome and absent gaze palsy has been identified, with less severe PSP-tau pathology. CONCLUSIONS: In recognition of his seminal observations, we propose that the classic clinical presentation of PSP-tau pathology be renamed Richardson's disease, and that the commonest clinical variant be termed PSP-parkinsonism.
Authors: Naomi Kouri; Melissa E Murray; Anhar Hassan; Rosa Rademakers; Ryan J Uitti; Bradley F Boeve; Neill R Graff-Radford; Zbigniew K Wszolek; Irene Litvan; Keith A Josephs; Dennis W Dickson Journal: Brain Date: 2011-09-20 Impact factor: 13.501
Authors: Naomi Kouri; Jennifer L Whitwell; Keith A Josephs; Rosa Rademakers; Dennis W Dickson Journal: Nat Rev Neurol Date: 2011-04-12 Impact factor: 42.937
Authors: Naomi Kouri; Kenichi Oshima; Makio Takahashi; Melissa E Murray; Zeshan Ahmed; Joseph E Parisi; Shu-Hui C Yen; Dennis W Dickson Journal: Acta Neuropathol Date: 2013-01-31 Impact factor: 17.088
Authors: Athena L Chen; David E Riley; Susan A King; Anand C Joshi; Alessandro Serra; Ke Liao; Mark L Cohen; Jorge Otero-Millan; Susana Martinez-Conde; Michael Strupp; R John Leigh Journal: Front Neurol Date: 2010-12-03 Impact factor: 4.003
Authors: Helen Ling; H Ling; R de Silva; L A Massey; R Courtney; G Hondhamuni; N Bajaj; J Lowe; J L Holton; A Lees; T Revesz Journal: Neuropathol Appl Neurobiol Date: 2014-02 Impact factor: 8.090
Authors: Nobutaka Sakae; Octavio A Santos; Otto Pedraza; Irene Litvan; Melissa E Murray; Ranjan Duara; Ryan J Uitti; Zbigniew K Wszolek; Neill R Graff-Radford; Keith A Josephs; Dennis W Dickson Journal: Neurology Date: 2020-06-09 Impact factor: 9.910